← Back to Search

Physician Education about Gabapentinoid Prescription for Overmedication (GABA-WHY Trial)

N/A
Waitlist Available
Led By Emily G McDonald, MD, MSc
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8-weeks post-hospital discharge
Awards & highlights

GABA-WHY Trial Summary

This trial will distribute educational brochures about deprescribing gabapentinoids to inpatients in two hospitals in Canada. This study aims to evaluate the effectiveness of this intervention on increasing gabapentinoid deprescription rates among study participants compared to control following hospital discharge.

Eligible Conditions
  • Overmedication
  • Gabapentin
  • Pregabalin

GABA-WHY Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8-weeks post-hospital discharge
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8-weeks post-hospital discharge for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gabapentinoid Discontinuation or Dose Reduction With Intention to Stop
Secondary outcome measures
Chronic Pain Intensity
Cognition
Gabapentinoid Dose Reduction Without Intention to Stop
+3 more

GABA-WHY Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: In-Hopsital Patient Educational Brochure and Physician Education about Gabapentinoid PrescriptionExperimental Treatment2 Interventions
During the intervention period, patients admitted to the study sites who qualify for the trial will receive an in-hospital educational brochure. Additionally, the medical team will attend an educational session about gabapentinoid prescription.
Group II: Usual Medical CareActive Control1 Intervention
During the control period, patients admitted to the study sites who qualify for the trial will receive a pharmacy medication reconciliation as part of usual medical care. Study participants will be informed that the goal of the trial is to evaluate medication use and medication changes after discharge, but they will not be informed that gabapentinoids are specifically being targeted. Medical staff will not receive specific information about the trial, or particular instructions with regards to deprescription during the control period.

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
450 Previous Clinical Trials
159,726 Total Patients Enrolled
Emily G McDonald, MD, MScPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre
~40 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top